Table 1

 Baseline demographic characteristics of participant groups

CharacteristicSulfasalazine (n = 50)Etanercept (n = 103)Etanercept and sulfasalazine (n = 101)Total (n = 254)
CRP, C reactive protein; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EuroQOL, EuroQuality of life; HAQ, Health Assessment Questionnaire; VAS, Visual Analogue Scale.
*p<0.05 between treatments (Mantel–Haenszel χ2 test).
Age (years), mean (SD)53.3 (12.8)51.3 (13.5)50.6 (12.3)51.4 (12.9)
Women, n (%)41.0 (82.0)81.0 (78.6)81.0 (80.2)203.0 (79.9)
Weight (kg), mean (SD)68.2 (13.1)71.7 (16.8)72.8 (15.5)71.5 (15.6)
Duration of disease (years), mean (SD)5.6 (4.4)7.1 (5.2)6.5 (5.1)6.6 (5.0)
Sulfasalazine dose (g/day), mean (SD)2.1 (0.4)2.1 (0.4)2.1 (0.5)2.1 (0.4)
Patients with a history of DMARDs, excluding sulfasalazine, n (%)29.0 (58.0)72.0 (69.9)59.0 (58.4)160.0 (63.0)
Patients using corticosteroids, n (%)*20.0 (40.0)61.0 (59.2)45.0 (44.6)126.0 (49.6)
Number of swollen joints, mean (SD)18.65 (11.1)19.1 (10.1)19.4 (10.4)19.1 (10.4)
Number of painful joints, mean (SD)31.3 (14.0)29.7 (14.7)31.3 (14.1)30.7 (14.3)
Pain VAS, mean (SD)58.8 (20.0)62.6 (21.7)58.5 (20.7)60.2 (21.0)
HAQ, mean (SD)1.6 (0.5)1.7 (0.6)1.6 (0.6)1.7 (0.6)
DAS, mean (SD)5.0 (1.1)5.1 (1.1)5.2 (1.2)5.1 (1.1)
EuroQOL VAS, mean (SD)44.6 (19.0)45.5 (21.3)43.1 (22.4)44.4 (21.2)
Morning stiffness (min), mean (SD)306.3 (394.5)323.3 (442.7)348.5 (469.7)330.0 (443.4)
ESR (mm at the end of the first hour), mean (SD)37.2 (28.2)37.4 (22.3)39.0 (25.8)38.0 (24.9)
CRP (mg/l), median11.5514.311.612.3